Development of Novel Isoindolone‐Based Compounds against Trypanosoma brucei rhodesiense
Dr. Daniel G. Silva,
Pim‐Bart Feijens,
Rik Hendrickx,
An Matheeussen,
Lucie Grey,
Prof. Dr. Guy Caljon,
Prof. Dr. Louis Maes,
Prof. Dr. Flavio S. Emery,
Dr. Anna Junker
Affiliations
Dr. Daniel G. Silva
QHeteM - Laboratório de Química Heterocíclica e Medicinal School of Pharmaceutical Sciences of Ribeirão Preto University of São Paulo Ribeirão Preto São Paulo 14040-903 Brazil
Pim‐Bart Feijens
Laboratory of Microbiology Parasitology and Hygiene (LMPH) University of Antwerp Universiteitsplein 1 Wilrijk B 2610 Belgium
Rik Hendrickx
Laboratory of Microbiology Parasitology and Hygiene (LMPH) University of Antwerp Universiteitsplein 1 Wilrijk B 2610 Belgium
An Matheeussen
Laboratory of Microbiology Parasitology and Hygiene (LMPH) University of Antwerp Universiteitsplein 1 Wilrijk B 2610 Belgium
Lucie Grey
Institute for Pharmaceutical and Medicinal Chemistry Westphalian Wilhelms-University Münster 48149 Münster Germany
Prof. Dr. Guy Caljon
Laboratory of Microbiology Parasitology and Hygiene (LMPH) University of Antwerp Universiteitsplein 1 Wilrijk B 2610 Belgium
Prof. Dr. Louis Maes
Laboratory of Microbiology Parasitology and Hygiene (LMPH) University of Antwerp Universiteitsplein 1 Wilrijk B 2610 Belgium
Prof. Dr. Flavio S. Emery
QHeteM - Laboratório de Química Heterocíclica e Medicinal School of Pharmaceutical Sciences of Ribeirão Preto University of São Paulo Ribeirão Preto São Paulo 14040-903 Brazil
Dr. Anna Junker
European Institute for Molecular Imaging (EIMI) Westphalian Wilhelms-University Münster 48149 Münster Germany
Abstract This study identified the isoindolone ring as a scaffold for novel agents against Trypanosoma brucei rhodesiense and explored the structure‐activity relationships of various aromatic ring substitutions. The compounds were evaluated in an integrated in vitro screen. Eight compounds exhibited selective activity against T. b. rhodesiense (IC50<2.2 μm) with no detectable side activity against T. cruzi and Leishmania infantum. Compound 20 showed low nanomolar potency against T. b. rhodesiense (IC50=40 nm) and no toxicity against MRC‐5 and PMM cell lines and may be regarded as a new lead template for agents against T. b. rhodesiense. The isoindolone‐based compounds have the potential to progress into lead optimization in view of their highly selective in vitro potency, absence of cytotoxicity and acceptable metabolic stability. However, the solubility of the compounds represents a limiting factor that should be addressed to improve the physicochemical properties that are required to proceed further in the development of in vivo‐active derivatives.
